• SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Home   >  Equity   >  Get Quotes

  • SENSEX Dec 10 2019 12:00
    40,239.88 -247.55 (-0.61%)
  • NIFTY Dec 10 2019 12:00
    11,856.80 -80.70 (-0.68%)
  • SENSEX Dec 10 2019 12:00
    40,239.88 -247.55 (-0.61%)
  • NIFTY Dec 10 2019 12:00
    11,856.80 -80.70 (-0.68%)
  • Nasdaq Dec 11 2019 04:30
    8,616.18 -5.64 (-0.07%)
  • DJIA Dec 11 2019 04:30
    27,881.72 -27.88 (-0.10%)
  • S&P 500 Dec 11 2019 04:30
    3,132.52 -3.44 (-0.11%)
  • Hang Seng Dec 10 2019 02:10
    26,436.62 -58.11 (-0.22%)
  • Crude Oil Dec 10 2019 11:45
    4,192.00 -5.00 (-0.12%)
  • Gold Dec 10 2019 11:45
    37,561.00 -22.00 (-0.06%)
  • Silver Dec 10 2019 11:45
    43,494.00 -8.00 (-0.02%)
  • Copper Dec 10 2019 11:45
    439.40 -0.10 (-0.02%)
  • Pound / Rupee Dec 23 2016 22:30
    93.33 -0.10 (-0.11%)
  • Dollar / Rupee Dec 23 2016 22:30
    70.96 -0.15 (-0.21%)
  • Euro / Rupee Dec 23 2016 22:30
    78.51 -0.30 (-0.38%)
  • Yen / Rupee Dec 23 2016 22:30
    0.65 0.00 (-0.12%)

Dr Lal Pathlabs Ltd

BSE Code : 539524 | NSE Symbol : LALPATHLAB | ISIN:INE600L01024| SECTOR: - |

NSE BSE
 

1,535.95

-87.55 (-5.39%) Volume 280564

10-Dec-2019 EOD

Prev. Close

1,623.50

Open Price

1,630.00

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

1,535.95(805)

 

Today’s High/Low 1,630.00 - 1,630.00

52 wk High/Low 1,698.50 - 890.95

Key Stats

MARKET CAP (RS CR) 12768.77
P/E 56.22
BOOK VALUE (RS) 124.9605821
DIV (%) 60
MARKET LOT 1
EPS (TTM) 27.25
PRICE/BOOK 12.2606663177508
DIV YIELD.(%) 0.39
FACE VALUE (RS) 10
DELIVERABLES (%) 33.54
4

News & Announcements

09-Dec-2019

Dr Lal Pathlabs Ltd - Dr. Lal Path Labs Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

28-Nov-2019

Dr Lal Pathlabs Ltd - Dr. Lal Path Labs Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

27-Nov-2019

Dr Lal Pathlabs Ltd - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

25-Nov-2019

Dr Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

09-Nov-2019

Board of Dr. Lal PathLabs recommends Interim Dividend

19-Oct-2019

Dr. Lal PathLabs to hold board meeting

29-Jul-2019

Dr. Lal PathLabs announces board meeting date

18-May-2019

Board of Dr. Lal PathLabs recommends final dividend

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Advanced Micronic Devices Ltd 517552
Apollo Hospitals Enterprise Ltd 508869 APOLLOHOSP
Artemis Global Life Sciences Ltd 540616 AGLSL
Aspira Pathlab & Diagnostics Ltd 540788
Aster DM Healthcare Ltd 540975 ASTERDM
Casil Health Products Ltd(merged) 523254
CDR Health Care Ltd 523353
Centenial Surgical Suture Ltd 531380
Chennai Meenakshi Multispeciality Hospital Ltd 523489
Cure Spects Laser Ltd 531356
Datt Mediproducts Ltd 532171 DATTMEDI
Deccan Hospital Corporation Ltd (Merged) 523258
Dhanvantri Jeevan Rekha Ltd 531043
Digiflex India Ltd 526111
Disposable Medi - Aids Ltd 523540
Dolphin Medical Services Ltd 526504
Dr Agarwals Eye Hospital Ltd 526783
Dr Lalchandani Labs Ltd 541299
Emaai Pharma Ltd 524756
Fidelity Industries Ltd (Wound-up) 526425
Fortis Healthcare Ltd 532843 FORTIS
Fortis Malar Hospitals Ltd 523696
Gil Hospitals Ltd (Wound-up) 526063
Healthcare Global Enterprises Ltd 539787 HCG
Indraprastha Medical Corporation Ltd 532150 INDRAMEDCO
Invicta Meditek Ltd 523844
Iswar Medical Services Ltd 507480 ISWARMEDIC
Kemwell International Ltd 530827
Keshlata Cancer Hospital Ltd 40450
Kids Medical Systems Ltd 540812
KMC Speciality Hospitals (India) Ltd 524520
Kovai Medical Center & Hospital Ltd 523323 KOVAI
La Medical Devices Ltd (Wound-up) 524772
Lifeline Injects Ltd 523379
Lokmanya Industries Ltd 526421
Looks Health Services Ltd 534422
Lotus Eye Hospital & Institute Ltd 532998 LOTUSEYE
Maestros Mediline Systems Ltd 501209
Medinova Diagnostic Services Ltd 526301
Metropolis Healthcare Ltd 542650 METROPOLIS
Monozyme India Ltd 522199
N G Industries Ltd 530897
Narayana Hrudayalaya Ltd 539551 NH
New World Medical (India) Ltd 524496
Noida Medicare Centre Ltd 523670
Nova Surgikos Ltd 524762
Opto Circuits (India) Ltd 532391 OPTOCIRCUI
Pramila Kidney Hospitals Ltd 40265
Raaj Medisafe India Ltd 524502
Regency Hospital Ltd 526403
Safire Global Medicare Ltd 524418 CDRMEDICAL
Sangam Health Care Products Ltd 531625
Secunderabad Healthcare Ltd 524540
Shalby Ltd 540797 SHALBY
Sharma East India Hosp and Medical Research Ltd 524548
Shiva Medicare Ltd 524602
Siemens Healthcare Diagnostics Ltd(merged) 506559
Soni Medicare Ltd 539378
Sterling (Gujarat) Hospitals Ltd 531741
Surgiplast Ltd 523077
Surlux Diagnostic Ltd 507854
Surlux Health Centres Ltd 523265
Surlux Mediquip Ltd 523515
Tamilnad Hospital Ltd 523443
Tejnaksh Healthcare Ltd 539428
Thyrocare Technologies Ltd 539871 THYROCARE
Transgene Biotek Ltd 526139
Transmedica (India) Ltd 526461
Transpact Enterprises Ltd 542765
Twenty First Century Medicare Ltd 40212
United Diagnostic International Ltd 523485

Share Holding

Category No. of shares Percentage
Total Foreign 21526371 25.83
Total Institutions 8417525 10.10
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 591486 0.71
Total Promoters 47431898 56.91
Total Public & others 5374330 6.45
Total 83341610 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Dr Lal Pathlabs Ltd

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. The catalogue of services includes 1,110 test panels, 2,028 pathology tests and 1,561 radiology and cardiology tests. Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt Ltd' The Company was incorporated as Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7, 2015. Consequently, the name of our Company was changed to Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the company with the company with effect from 1 April 2017. The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh. On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017. Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international

Dr Lal Pathlabs Ltd Chairman Speech

Dear Shareholders,

As a leading consumer healthcare brand, we believe that Dr. Lal PathLabs (DLPL) is the vanguard of transformation in the diagnostics industry. The largely un-organized sector is in the process of transitioning gradually to a more formalized set-up spurred in part, by the advent of last year's GST implementation. We find that our hub-and-spoke model lends itself well to these dynamics, wherein we are charting our growth as per our strategic imperatives in an evolving landscape. FY18 has served as a sterling example of how a well-trusted, established chain like DLPL can continue to create scale and brand equity in the face of multiple headwinds.

As we move forward, there are a few trends that we see emerging; the formal sector is expected to witness healthy competitive intensity from fund-backed players, who are seeking to accelerate growth. This trend, however is moderating and will instead serve to expand the ambit of the branded chains overall. The other trend is of greater regulatory oversight from both a pricing and compliance point of view. We see DLPL traversing these realities with confidence too, stemming from the trust the name inspires.

Looking at a macro perspective, the coming decades will see greater public spending on healthcare through dedicated and broad-based schemes aimed at the most vulnerable sections of society. Both Central and State Governments have created programs to formalize the delivery of services. The National Health Protection Mission (NHPM), a part of Ayushman Bharat, which intends to provide targeted health coverage to approximately 500 million of Economically Weaker Section (EWS) citizens comes under the umbrella of the Government's stellar health initiative. As an established chain, we see a role for ourselves in this scenario.

A methodical approach to expanding our network has helped to create scale and in-line with our strategic vision, we will stay on this path. We firmly believe that volume growth is the prime driver of the operation and our initiatives are lined-up to make that possible.

Over the coming months, we seek to increase volumes by way of expansion from the East and Central regions given that we have commissioned the Reference Laboratory at Kolkata and the traction building up in the wellness & preventive portfolio through bundled packages, under the umbrella brand name SwasthFit which provide greater value to our customers. This will be in addition to growth that will be realized from higher sampling across our existing network where we are adding capacity as per plan.

At this opportunity, I would also like to place on record my sincere thanks to all our well-wishers, associates, vendors, customers, employees and members of the Board who over several years have contributed to the success of your Company. Lastly, I would also like to thank all the stakeholders for their loyalty and continuous support in helping us achieve our vision of bringing quality health care to India's masses.

Warm Regards

(Hony) Brig. Dr. Arvind Lal

Chairman & Managing Director

   

Dr Lal Pathlabs Ltd Company History

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. The catalogue of services includes 1,110 test panels, 2,028 pathology tests and 1,561 radiology and cardiology tests. Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt Ltd' The Company was incorporated as Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7, 2015. Consequently, the name of our Company was changed to Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the company with the company with effect from 1 April 2017. The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh. On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017. Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international

Dr Lal Pathlabs Ltd Directors Reports

Dear Members,

Your Directors have pleasure in presenting the 25th Annual Report on the business and operations of your Company along with the audited statement of accounts for the year ended March 31, 2019.

FINANCIAL RESULTS

The Financial performance of your Company for the year ended March 31, 2019 is summarized below:

Particulars Year ended March 31, 2019 (In Rs. Million) Year ended March 31, 2018 (In Rs. Million) Year ended March 31, 2019 (In Rs. Million) Year ended March 31, 2018 (In Rs. Million)
Consolidated Consolidated Standalone Standalone
Total Income 12,493.67 10,881.38 12,113.93 10,555.56
Total Expenses 9,488.19 8,268.23 9,190.26 7,997.98
Profit/(Loss) before Tax (PBT) 3,005.48 2,613.15 2,923.67 2557.58
Profit/(Loss) after Tax (PAT) 2,004.67 1,717.52 1,954.38 1682.70

FINANCIAL PERFORMANCE

During the year under review, the consolidated income of the Company increased to Rs.12,493.67 million compared to Rs.10,881.38 million in the previous year, registering growth of 14.8%. Net profit after tax for the group increased to Rs.2,004.67 Million from Rs.1,717.85 million representing a growth of 16.7%.

During the year under review, the standalone income of the Company increased to Rs.12,113.93 million compared to Rs.10,555.56 million in the previous year, registering growth of 14.8%. The standalone profit after tax for the year increased by 16.2% to Rs.1,954.38 million compared to Rs.1682.70 million in the previous year.

CONSOLIDATED ACCOUNTS

The consolidated financial statements of your Company for the Financial Year 2018-19, are prepared in compliance with applicable provisions of the Companies Act, 2013 ('the Act"), Accounting Standards and Listing Regulations as prescribed by the Securities and Exchange Board of India (SEBI). The consolidated financial statements have been prepared on the basis of audited financial statements of the Company and its Subsidiary Companies, as approved by their respective Board of Directors.

DIVIDEND

During the Financial Year, your Company declared and paid an interim dividend of Rs.2.50/- per equity share of face value of Rs.10/- each. In addition, your Directors are pleased to recommend a dividend of Rs.3.50/- per equity share of face value of Rs.10/- each as final dividend for the Financial Year 2018-19, for approval of the shareholders at the ensuing Annual General Meeting ("AGM") of the Company.

If approved by the members, the total dividend for the Financial Year shall be Rs.6/- per equity share of face value of Rs.10/- each.

The Dividend Distribution Policy of the Company is attached herewith as Annexure 1 and forms an integral part of the Annual Report.

The said policy is also available at the website of the Company at:

https://www.lalpathlabs.com/pdf/brochures/Dividend Distribution Policy may.pdf

TRANSFER TO RESERVES

During the year under review, no amount has been transferred to the General Reserve of the Company.

AMALGAMATION OF DELTA RIA AND PATHOLOGY PRIVATE LIMITED

The Board of Directors of your Company in their meeting held on May 12, 2017, approved a Scheme of Amalgamation of Delta Ria And Pathology Private Limited, a wholly owned subsidiary of the Company with the Company, subject to requisite approvals under Section 230 to 232 of the Companies Act, 2013.

The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23,2018 and December 11, 2018 respectively.

The NCLT orders were filed with the Registrar of Companies, NCT of Delhi & Haryana on January 01, 2019. (Being the effective date).

Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017 (being the appointed date) and consequently stands dissolved without winding up.

The necessary accounting entries giving effect to the Scheme were passed in the books of accounts of the Company.

CHANGES IN SHARE CAPITAL

Paid-up Share Capital

During the Financial Year 2018-19, the paid-up equity share capital of the Company has been increased from Rs.83,33,27,440/- to Rs.83,34,16,100/- pursuant to allotment of 8,866 Equity Shares of Rs.10/- each under the Employee Stock Option Plan 2010 of the Company.

Authorized Share Capital

During the Financial Year 2018-19, the Authorized Share Capital got increased from Rs.1,07,90,00,000/- to Rs.1,07,95,00,000/- by virtue of the NCLT order passed sanctioning the Scheme of Amalgamation of Delta Ria & Pathology Private Limited with the Company.

EMPLOYEES STOCK OPTION PLAN / SCHEME

During the year under review, there has been no material change in the ESOP-2010/ RSU-2016 Scheme(s) of the Company and these Schemes continue to be in compliance with relevant/applicable ESOP Regulations/clauses.

Further the details required to be provided under the SEBI (Share Based Employee Benefits) Regulations, 2014 are disclosed on the website of the Company and can be accessed at https://www.lalpathlabs.com/pdf/Information-as-per-SEBI-(SBEB)- Regulations-FY-19.pdf

SUBSIDIARIES

A report on the performance and financial position of each of the subsidiaries for the financial year ended March 31, 2019 as per the Companies Act, 2013 is set out in Annexure 2 and forms an integral part of this Annual Report.

The annual accounts of the subsidiaries shall also be made available to the Members of the Company/Subsidiary Companies seeking such information at any point of time. The annual accounts of the subsidiaries are also available for inspection for any Member during business hours at the Registered Office of the Company and Subsidiary Companies and have also been uploaded on the website of the Company (www.lalpathlabs.com).

The Company has formulated a policy for determining material subsidiaries. The said policy is also available on the website of the Company at https://www.lalpathlabs.com/pdf/Policy-for- determining-Material-Subsidiaries.pdf.

During the year under review, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12,2018, respectively, as wholly owned subsidiaries of the Company.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Management Discussion and Analysis Report forms an integral part of this Annual Report and gives details of the overall industry structure, developments, performance and state of affairs of the Company's business and other material developments during the Financial Year.

BUSINESS RESPONSIBILITY REPORT

The Business Responsibility Report ('BRR') forms an integral part of this Annual Report. The BRR provides a detailed overview of initiatives taken by your Company from environmental, social and governance perspectives.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION

Material changes and commitments, other than disclosed as part of this report, affecting the financial position of the Company are set out in Note 49 and Note 44 to the Standalone and Console Financial Statements respectively.

PUBLIC DEPOSITS

During the Financial Year 2018-19, your Company has not accepted any deposit within the meaning of Sections 73 and 74 of the

Companies Act, 2013 read together with the Companies (Acceptance of Deposits) Rules, 2014.

CORPORATE GOVERNANCE REPORT

In compliance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate report on corporate governance along with a certificate from the Practicing Company Secretary on its compliance, forms an integral part of this Annual Report.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are provided in the prescribed format and annexed herewith as Annexure 3 to this Report.

The statement containing particulars of employees as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is provided in a separate annexure forming part of this report. Further, the Report and the accounts are being sent to the members excluding the aforesaid annexure. In terms of Section 136 of the Act, the said annexure is open for inspection at the Registered Office of the Company during the business hours till the date of the ensuing Annual General Meeting. Any shareholder interested in obtaining a copy thereof may write to the Company Secretary of the Company.

AUDIT COMMITTEE

The composition of Audit Committee has been detailed in the Corporate Governance Report, forming part of this Annual Report.

All recommendations made by the Audit Committee have been accepted by the Board of Directors.

DIRECTORS

I. Retirement by rotation and subsequent re-appointment:

Mr. Rahul Sharma (DIN: 00956625), Non-Executive Director of the Company is liable to retire by rotation at the ensuing AGM pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and being eligible offers himself for reappointment. Appropriate resolution for his re-appointment is being placed for the approval of the shareholders of the Company at the ensuing AGM. A Brief profile of Mr. Rahul Sharma and other related information has been detailed in the Notice convening the 25th AGM of your Company.

II. Appointment(s)

(1) Ms. Somya Satsangi (DIN: 07275574) was appointed as an Additional Director (Independent) for a period of 3 Years w.e.f February 8, 2019.

(2) Dr. Archana Lal Erdmann (DIN: 08432506) was appointed as an Additional Director (Non-Executive), liable to retire by rotation w.e.f. May 17, 2019.

According to the provisions of Section 161 of the Companies Act, 2013 additional directors shall hold office upto the date of the ensuing Annual General Meeting.

The Board considers their appointment in the interest of the Company and hence recommended the same to the shareholders for approval.

Brief resume/details regarding Director proposed to be reappointed as above are furnished in the Notice of the AGM.

III. Resignation:

Mr. Arun Duggal, resigned as an Independent Director with effect from March 1, 2019.

The Board places on record its appreciation for the services rendered by him during his association with the Company.

Declaration of Independence from Independent Directors

Your Company has received declarations from all the Independent Directors (Including Ms. Somya Satsangi) confirming that they meet the criteria of independence as prescribed under the provisions of Companies Act, 2013 read with the Schedules and Rules issued thereunder as well as SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In the opinion of the Board, Independent Directors fulfill the conditions specified in Companies Act, 2013 read with the Schedules and Rules issued thereunder as well as SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are independent from Management.

KEY MANAGERIAL PERSONNEL

During the year under review Mr. Dilip Bidani resigned as the Chief Financial Officer of the Company and in his position Mr. Ved Prakash Goel was appointed as the Chief Financial Officer w.e.f August 10, 2018.

In accordance with the provisions of Sections 2(51), 203 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the following are the Key Managerial Personnel of the Company as on March 31, 2019

1. (Hony) Brig. Dr. Arvind Lal - Chairman and Managing Director

2. Dr. Om Prakash Manchanda - CEO and Whole Time Director

3. Dr. Vandana Lal - Whole Time Director

4. Mr. Ved Prakash Goel - Chief Financial Officer; and

5. Mr. Rajat Kalra - Company Secretary and Legal Head

ANNUAL EVALUATION OF BOARD'S PERFORMANCE:

Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has carried out annual evaluation of (i) its own performance; (ii) Individual Directors Performance; and (iii) Performance of all committees of Board for the Financial Year 2018-19.

A structured questionnaire was prepared after taking into consideration the inputs received from Nomination and Remuneration Committee, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Board culture, execution and performance of specific duties, obligations and governance. A separate exercise was carried out to evaluate the performance of individual Directors, who were evaluated on parameters such as level of engagement and contribution, independence of judgment, safeguarding the interest of the Company and its minority shareholders etc. The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Non - Independent Directors was carried out by the Independent Directors.

The Directors expressed their satisfaction with the evaluation process.

REMUNERATION POLICY

In compliance with the provision of Section 178 of the Companies Act, 2019, the Board has, on the recommendation of the Nomination & Remuneration Committee of the Company, framed a policy for selection and appointment of Directors, Key Managerial Personnel, Senior Management and their remuneration.

The Nomination and Remuneration Policy is set out as Annexure 4 and forms an integral part of this Annual Report and can also be accessed at the website of the Company at the following web link:

https://www.lalpathlabs.com/pdf/brochures/Nomination and Remuneration Policy may.pdf

NUMBER OF MEETINGS OF THE BOARD AND ITS COMMITTEES & DETAILS OF ATTENDANCE

The details of the meetings of the Board of Directors and its Committees and attendance by Directors/Members, convened during the Financial Year 2018-19 are given in the Corporate Governance Report, which forms an integral part of this Annual Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) of the Companies Act, 2013, the Directors confirm that:

a) in the preparation of the annual accounts for the Financial Year ended March 31, 2019, the applicable accounting standards and Schedule III of the Companies Act, 2013, have been followed and there are no material departures from the same;

b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of your Company as at March 31, 2019 and of the profit and loss of the Company for the Financial Year ended March 31, 2019;

c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) the annual accounts have been prepared on a 'going concern' basis;

e) proper internal financial controls laid down by the Directors were followed by the Company and that such internal financial controls are adequate and were operating effectively; and

f) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

AUDITORS AND AUDITORS' REPORT

I. Statutory Auditors

The shareholders at the 23rd AGM, approved the appointment of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration No. 117366W/W - 100018), as the Statutory Auditors, for a period of five (5) years i.e. from the conclusion of the 23rd AGM till the conclusion of 28th AGM of the Company subject to ratification of appointment by the shareholders at every Annual General Meeting.

However, pursuant to the notification dated May 07, 2018, issued by the Ministry of Corporate Affairs, the requirement for ratification of Statutory Auditors at every Annual General Meeting has been done away with.

Accordingly, M/s. Deloitte Haskins & Sells LLP, Chartered Accountants shall continue as the Statutory Auditors of the Company till the conclusion of 28th AGM in terms of the shareholders resolution dated July 20, 2017 passed at the 23rd AGM.

The Statutory Auditors of the Company have not reported any fraud as specified under the second proviso of Section 143(12) of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) for the time being in force).

The Auditors' Report for the Financial Year ended March 31, 2019, does not contain any qualification, reservation or adverse remark.

Further the Auditors' Report being self-explanatory does not call for any further comments from the Board of Directors.

II. Maintenance of cost Records and Cost Auditors

In terms of the Section 148 of the Companies Act, 2013 read with Companies (Cost Records and Audit) Rules, 2014, the Company is required to maintain cost accounting records and get them audited every year. Accordingly such accounts and records were made and maintained.

The Board of Directors on the basis of recommendations from Audit Committee has appointed M/s A.G. Agarwal & Associates, Cost Accountants, as cost auditors of the Company for the Financial Year 2019-20 at a fee of Rs.60,000 (Rupees Sixty Thousand only) plus applicable taxes and out of pocket expenses subject to the ratification of the said fees by the shareholders at the ensuing AGM.

III. Secretarial Auditors

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, your Company had appointed M/s PDS & Co., Company Secretaries ("Secretarial Auditors") to conduct the Secretarial Audit of your Company for the Financial Year 2018-19.

The Secretarial Audit Report for the Financial Year ended March 31, 2019 is annexed herewith as Annexure 5 and forms an integral part of this Annual Report. The Secretarial Audit Report does not contain any qualification, reservation or adverse remark.

EXTRACT OF ANNUAL RETURN

The extract of the Annual Return of the Company as on March 31, 2019 in Form MGT- 9 in accordance with Section 92(3) of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 is available on the website of the Company at https://www.lalpathlabs.com/pdf/Extract of Annual Return-MGT-9-FY%202018-19 7july2019.pdf and is set out herewith as Annexure 6 and forms an integral part of this Annual Report.

RELATED PARTY TRANSACTIONS

In compliance with the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, your Company has formulated a Policy on Related Party Transactions which is also available on Company's website at https:// www.lalpathlabs.com/pdf/Policv-on-Related-Partv-Transactions.pdf.

The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties. All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length.

All related party transaction entered during the year were in Ordinary Course of the Business and on Arm's Length basis. No Material Related Party Transactions, i.e. transactions exceeding ten percent of the annual consolidated turnover as per the last audited financial statements, were entered during the year by your Company. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3)(h) of the Companies Act, 2013 in Form AOC-2 is not applicable.

LOANS AND INVESTMENTS

Details of Loans, Guarantees given and Investments made by the Company during Financial Year 2018-19 within the meaning of Section 186 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Schedule V of the SEBI Listing Regulation, are set out in Note 48 to the Standalone Financial Statements of the Company.

RISK MANAGEMENT

Your Company recognizes that risk is an integral part of business and is committed to managing the risks in a proactive and efficient manner. Your Company periodically assesses risk elements in the internal and external environment, along with the cost of treating such risk elements and incorporates risk treatment plans in its strategy, business and operational plans. As on the date of this report, the Company does not foresee any critical risk, which threatens its existence.

Your Company, through its risk management policy, strives to contain impact and likelihood of the risks within the risk appetite as agreed from time to time with the Board of Directors. The Company has a Risk Management Committee to identify elements of risk in different areas of operations; the details of the Risk Management Committee are included in the Corporate Governance Report.

VIGIL MECHANISM

Your Company has a Vigil Mechanism in place as required under Section 177 of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. No matter was reported during the year under review. More details in this regard have been outlined in the Corporate Governance Report annexed to this report and are also available under Investor Section on the Company's web-site (www.lalpathlabs.com).

CORPORATE SOCIAL RESPONSIBILITY

For your Company, Corporate Social Responsibility (CSR) means the integration of social, environmental and economic concerns in its business operations. CSR involves operating Company's business in a manner that meets or exceeds the ethical, legal, commercial and public expectations that society has of businesses. In alignment with vision of the Company, through its CSR initiative, your Company will enhance value creation in the society through its services, conduct and initiatives, so as to promote sustained growth for the society.

The Board of Directors of your Company has further formulated and adopted a policy on Corporate Social Responsibility which can be accessed at our website at https://www.lalpathlabs.com/pdf/ brochures/CSR-Policy.pdf.

The CSR Policy of your Company outlines the Company's philosophy for undertaking socially useful programs through the creation of a CSR Trust for welfare and sustainable development of the community at large as part of its duties as a responsible corporate citizen. During the year under review, there has been no change in the policy.

The composition of CSR committee and disclosure as per Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 is annexed as Annexure 7 and forms an integral part of this Annual Report.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment Policy in compliance with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment.

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee as specified under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The Company conducts sessions for employees to build awareness amongst employees about the Policy and the provisions of Prevention of Sexual Harassment of Women at Workplace Act.

During the period under review, 6 (Six) complaints were received by the ICC and the same were disposed off.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014, is set out hereunder:

I. Conservation of energy and Technology Absorption

• Maintaining power factor (PF) up to .99 (unity). Maintaining up to- 0.9994.

• Recycling of RO waste water and treated lab waste as part of water conservation.

• Post reports of energy Audit of Lab, chiller load is directed to two of the more efficient chillers.

• Descaling done of chillers to improve efficiency and retuned the evaporator pressure drop and condenser water flow to maximize efficiency of chillers.

• Replaced cooling tower fills and eliminator to improve efficiency of cooling tower.

• Reduction in number of chillers operational during off peak hours, and switching on only cooling water pump to maintain set temperature.

• Installing split AC in areas which are operating extended hours to avoid the running of entire floor AHU.

• All utilities functions are operated during off peak hours, this gives advantage of off peak hours Tariff rebate extended by NDPL.

• Optimizing operations of two elevators during peak and off time.

• During winters when the load demand is reduced, we proactively shut down one of the transformer alternately to save transformer loss.

• LED lights change from conventional lights for energy saving exercise.

• Installed 50KW Solar Rooftop power plant system for generation of natural energy saving.

• Additional 50KW Solar Rooftop power plant system for generation of natural energy saving planned for installation this year for both the reference labs at Rohini (NRL) and Kolkata (KRL).

• Replaced the existing cold room unit by energy efficient units.

• Kolkata reference laboratory(KRL) received the "LEED 2009 GOLD certification" for Leadership in Energy and Environmental Design (LEED). LEED is a third party verification system for green buildings developed by the U.S. Green Building Council (USGBC). The certification covers all phases of development from design and construction, operations and maintenance to significant retrofits.

II. Foreign exchange earnings and outgo

S.No. Particulars Amount (In Rs. Million)
1 Foreign Exchange Earnings 155.10
2 Foreign Exchange Outgo 88.30

INTERNAL FINANCIAL CONTROLS

Your Company has in place an adequate internal financial control framework with reference to financial and operating controls thereby ensuring orderly and efficient conduct of its business, including adherence to the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, and timely preparation of reliable financial information.

During Financial Year 2018-19, such controls were tested and no reportable material weakness in the design or operation was observed.

The Directors have in the Directors Responsibility Statement confirmed the same to this effect.

SIGNIFICANT/MATERIAL ORDERS PASSED BY THE REGULATORS

There are no significant/material orders passed by the Regulators or Courts or Tribunals impacting the going concern status of your Company and its operations in future.

COMPLIANCE OF SECRETARIAL STANDARDS

The Company has duly complied with Secretarial Standards issued by the Institute of Company Secretaries of India on Meetings of the Board of Directors (SS-1) and shareholders (SS-2).

APPRECIATION

Your Directors wish to convey their gratitude and place on record their appreciation for all the employees at all levels for their hard work, solidarity, cooperation and dedication during the year. Your Directors sincerely convey their appreciation to customers, shareholders, vendors, bankers, business associates, regulatory and government authorities for their continued support.

For and on behalf of Board of Directors
(Hony) Brig. Dr. Arvind Lal
Chairman & Managing Director
Place: New Delhi DIN: 00576638
Date: May 17, 2019

Annexure - 1

Policy on Dividend Distribution

1. Introduction

Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") notified on July 08, 2016 provides for top five hundred listed entities based on market capitalization (calculated as on March 31 of every financial year) to formulate a dividend distribution policy.

Considering that the Company is amongst the top 500 listed entities based on Market Capitalization as on 31st March 2016, the Board of Directors of Dr. Lal PathLabs Limited ("Company") have adopted this policy on Dividend Distribution.

2. Objectives & Scope

This Policy lays downs the broad framework which will act as a guiding principle for the purpose of declaring or recommending dividend during or for any financial year, by the Company.

Through this policy, the Company shall endeavour to bring a transparent and consistent approach to its dividend pay-out plans.

The Policy, however, is not an alternative to the decision making process of the Board for recommending Dividend and the Board may take into consideration other factors as well in addition to the ones enumerated in this policy.

3. Definitions

3.1. "Act" shall mean the Companies Act, 2013 including the Rules made thereunder, as amended from time to time.

3.2. "Applicable Laws" shall mean the Companies Act, 2013 and Rules made thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; as amended from time to time and such other act, rules or regulations which provides for the distribution of dividend.

3.3. "Company" shall mean Dr. Lal PathLabs Limited.

3.4. "Board" or "Board of Directors" shall mean Board of Directors of the Company.

3.5. "Dividend" shall mean Dividend as defined under Companies Act, 2013.

3.6. "Policy or this Policy" shall mean the Policy on Dividend Distribution.

3.7. "SEBI Regulations" shall mean the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 together with the circulars issued thereunder, including any statutory modification(s) or re-enactment(s) thereof for the time being in force.

4. Parameters for declaration of Dividend

In line with the philosophy stated above, the Board of Directors shall consider the following parameters for declaration of dividend:

4.1 Financial Parameters

> Consolidated Net operating profit after tax;

> Working Capital requirements;

> Capital expenditure requirements;

> Likelihood of crystallization of contingent liabilities, if any;

> Resources required to fund acquisition of brands/ business(es);

> Cash flow required to meet contingencies;

> Outstanding borrowings;

4.2 Internal Factors

> Potential opportunities available for growth/expansion

> Past Dividend Trends;

> Expectation of major shareholders;

> Prudential requirements for cash conservation

4.3 External Factors

> Prevailing legal requirements, regulatory conditions or restrictions laid down under applicable laws including tax laws;

> Dividend Pay-out ratios of companies in similar industries

> Economic Environment

Post consideration of the above factors, the Board shall take an informed decision about the dividend pay-out ratio and shall strive to maintain the same in the range of 10%-50% of the Profit after Tax (PAT) on Standalone Financials for the concerned Financial Year.

5. Circumstances under which the shareholders may or may not expect dividend:

The Shareholders of the Company may expect dividend only if the Company is having surplus funds after providing for all expenses, depreciation, other non-cash charges etc. and complying all other statutory requirements of the Applicable Law.

The Board shall consider the factors mentioned under Clause 4 above and before determination of any dividend payout, analyze the prospective opportunities and threats, viability of the option of dividend payout or retention etc. The Board shall not recommend dividend if they are of the opinion that it is financially not prudent to do so.

6. Utilization of retained earnings

The Board may retain its earnings in order to make better use of the available funds and increase the value of the stakeholders in the long run. The decision of utilization of the retained earnings of the Company shall be based on the following factors:

> Market expansion plan;

> Product/Service expansion plan;

> Modernization plan;

> Diversification of business;

> Long term strategic plans;

> Replacement of capital assets;

> Where the cost of debt is expensive;

> Such other criteria as the Board may deem fit from time to time.

7. Provision with regard to various classes of shares

The holders of the equity shares of the Company, as on the record date, are entitled to receive dividends. Since the Company has issued only one class of equity shares with equal voting rights, all the members of the Company shall be entitled to receive the same amount of dividend per share. The policy shall be suitably revisited at the time of issuance of any new class of shares depending upon the nature and guidelines prevailing thereon.

8. Amendment(s):

> The Board of Directors may review or amend this policy, in whole or in part, from time to time, as it may deem fit.

> In case of any amendment(s) issued by the relevant authorities, not being consistent with the provisions laid down under this Policy, then such amendment(s) shall be treated as part of this Policy and this Policy shall stand amended accordingly from the effective date as laid down under such amendment(s).

> In case of any clarification(s), circular(s) etc. issued by the relevant authorities, not being consistent with the provisions laid down under this Policy, then this Policy shall be read along with such clarification(s), circular(s) so issued , from the effective date as laid down under such clarification(s), circular(s) etc.

9. Disclosures

The Company shall disclose this policy in its Annual Report & website.

Annexure - 2

FORM AOC-1

(Pursuant to first proviso to sub-section (3) of Section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries / associate companies / joint ventures

s. No. Name of Subsidiary Date on which subsidiary was acquired Country of Incorporation Reporting Currency Closing exchange rate against Indian Rupee as on Mar 31,2019 %of Holding Capital Other Equity Total Assets Total Liabilites Investments Turnover Profit before taxation Provision for taxation Profit after taxation Proposed dividend
(i) (2) (3) (4) (5) (6) U) (8) (9) (10) (u) (12) (13) (14) (15) (16)
1 Paliwal Diagnostics Private Limited 14/08/2008 India 1 80% 0.16 157.52 180.83 23.15 - 282.60 94.00 28.55 65.45 -
2 Paliwal Medicare Private Limited 14/08/2008 India 1 80% 0.10 53.48 57.35 3.77 - 44.38 8.00 2.02 5.98 -
3 APL Institute of Clinical Laboratory & Research Private Limited 27/02/2014 India ? 1 100% 0.10 11.99 17.15 5.06 35.50 0.30 (0.10) 0.40
4 Dr. Lai PathLabs International B.V. 20/03/2014 Netherlands r - - - - - - - - - - - -
5 Dr. Lai PathLabs Nepal Private Limited 23/08/2016 Nepal r* 0.620572 100% 25.05 (8.31) 23.02 6.28 - 41.25 1.59 0.54 1.05 -
6 Dr. Lai PathLabs Bangladesh Pvt Ltd. 16/10/2017 Bangladesh r** 0.825351 71.83% 31.90 12.73 65.35 20.72 - 34.25 (4.43) 0.57 (5.00) -
7 Dr. Lai Ventures Private Limited 10/12/2018 India ? 1 100% 1.00 (0.28) 0.78 0.06 - - (0.31) (0.03) (0.28) -
8 PathLabs Unifiers Private Limited 12/12/2018 India 1 100% 1.00 (0.75) 0.31 0.06 - - (0.78) (0.03) (0.75) -

* Functional Currency is EUR

** Functional Currency is NPR

*** Functional Currency is BDT Notes:

a. Dr. Lai PathLabs International B.V., incorporated on March 20,2014, is yet to commence its operations. No Investments have been made by the Company.

b. The Board of Directors in their meeting, held on 12 May, 2017, approved the "Scheme of Amalgamation" of Delta Ria and Pathology Private Limited (Transferor Company), a wholly owned subsidiary, with the Company (Transferee Company) w.e.f. 1 April, 2017 (the appointed date). As per the said scheme the undertaking of the transferor company shall stand transferred to and vested in the transferee Company on a going concern basis without any further act, deed of matter.

The Scheme envisages transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company. Pursuant to the scheme coming into effect w.e.f. January 1,2019, all the equity shares held by the Transferee Company in Transferor Company stand automatically cancelled.

The amalgamation has been accounted for under section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.The difference between the carrying value of investments in the books of the Transferee Company and the amount of the net assets of Transferor Company has been adjusted in Capital Reserve as per the scheme. The impact of the amalagamation has been given from the date on which the Transferee Company obtained the control of the Transferor Company i.e. 21 December, 2016 in accordance with the pooling of interests method prescribed under Ind AS 103 Business Combinations.

c. The reporting period for all the subsidiaries is March 31,2019.

Annexure - 3

Disclosures pertaining to remuneration under Section 197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 for the year ended March 31, 2019.

A. The ratio of the remuneration paid to each director during the year to the median remuneration of the employees of the Company for the Financial Year:

S. No. Name of the Director Category Ratio of Remuneration to the median remuneration of the employees
1. (Hony) Brig. Dr. Arvind Lal Executive Director 80:1
2. Dr. Vandana Lal Executive Director 64:1
3. Dr. Om Prakash Manchanda* Executive Director & Chief Executive Officer 127:1
4. Mr. Rahul Sharma Non-Executive Director 4:1
5. Mr. Arun Duggal** Independent Non-Executive Director 6:1
6. Dr. Saurabh Srivastava Independent Non-Executive Director 7:1
7. Mr. Sunil Varma Independent Non-Executive Director 6:1
8. Mr. Anoop Mahendra Singh Independent Non-Executive Director 5:1
9. Mr. Harneet Singh Chandhoke Independent Non-Executive Director 5:1
10 Ms. Somya Satsangi*** Independent Non-Executive Director 0.79:1

"Does not include a non-cash (stock related) perk of Rs.1,74,60,700/- on exercise of Stock options.

"Mr. Arun Duggal resigned from the Board w.e.f. March 1, 2019

*** Ms. Somya Satsangi was appointed on the Board w.e.f. February 8, 2019

B. The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, in the Financial Year:

S. No. Name of the Director Category % Increase in Financial Year Remuneration in the
1. (Hony) Brig. Dr. Arvind Lal Executive Director 5
2. Dr. Vandana Lal Executive Director 5
3. Dr. Om Prakash Manchanda Executive Director & Chief Executive Officer 5
4. Mr. Rahul Sharma* Non-Executive Director N.A.
5. Mr. Arun Duggal Independent Non-Executive Director NIL
6. Dr. Saurabh Srivastava Independent Non-Executive Director NIL
7. Mr. Sunil Varma Independent Non-Executive Director NIL
8. Mr. Anoop Mahendra Singh Independent Non-Executive Director NIL
9. Mr. Harneet Singh Chandhoke Independent Non-Executive Director NIL
10. Ms. Somya Satsangi** Independent Non-Executive Director N.A.
11. Mr. Dilip Bidani*** Chief Financial Officer 7.51
12. Mr. Ved Prakash Goel**** Chief Financial Officer 7.89
13. Mr. Rajat Kalra Company Secretary 7.24

"Mr. Rahul Sharma was not entitled to any remuneration for the Financial Year 2017-18.

**Ms. Somya Satsangi was appointed on the Board w.e.f February 8, 2019.

"""Mr. Dilip Bidani resigned as the Chief Financial Officer on August 10, 2018.

""""Mr. Ved Prakash Goel was appointed as Chief Financial Officer w.e.f August 10,2018.

C. Percentage increase in the median remuneration of employees in the Financial Year:

The average percentage increase in the median remuneration of employees in the Financial Year is 18.03.

D. Number of permanent employees on the rolls of the Company:

The number of permanent employees on the rolls of the Company as of March 31, 2019 is 3,941.

E. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last Financial Year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

Average percentile increase in the salaries of employees other than the managerial personnel is 10.41% Average percentile increase in managerial personnel is 5.49% Not Applicable as Managerial Remuneration increase % is lower

F. Affirmation that the remuneration is as per the Remuneration Policy of the Company:

It is hereby confirmed that the remuneration is as per the Nomination and Remuneration Policy of the Company.

Annexure - 4

Nomination And Remuneration Policy

1. Introduction

In terms of Section 178 of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 , this policy on nomination and remuneration of Directors, Key Managerial Personnel (KMP), Senior Management and other employees of the Company has been formulated by the Board of Directors on the recommendation of Nomination and Remuneration Committee of the Company. This policy shall act as a guideline for determining, inter-alia, qualifications, positive attributes and independence of a Director, matters relating to the remuneration, appointment, removal and evaluation of performance of the Directors, Key Managerial Personnel, Senior Management and other employees.

2. Policy Objective

a. To lay down criteria for identifying persons who are qualified to become Directors and who may be appointed in Key Managerial and Senior Management positions and to recommend to the Board their appointment and removal.

b. To lay down criteria to carry out evaluation of every Director's /KMP/Senior Management Personnel and other employees performance.

c. To formulate criteria for determining qualification, positive attributes and Independence of a Director.

d. To recommend to the Board a policy, relating to remuneration of directors, key managerial personnel and other employees. While recommending such policy the Nomination and Remuneration Committee shall ensure:

i. The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully.

ii. Relationship of remuneration to performance is clear and meets appropriate performance benchmarks.

iii. Remuneration of Directors, Key Managerial Personnel and Senior Management involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company and its goals.

e. To formulate a Board Diversity Policy.

f. To recommend to the Board, all remuneration, in whatever form, payable to Senior Management

3. Definitions

a. "Board of Directors" means the "Board of Directors" of Dr. Lal PathLabs Limited, as constituted from time to time.

b. "Company" means Dr. Lal PathLabs Limited.

c. "Independent Director" means a Director of the Company, not being a Managing or Whole-Time Director or a Nominee Director and who is neither a Promoter nor belongs to the Promoter Group of the Company and who satisfies the criteria of independence as prescribed under the provisions of the Companies Act 2013 (including the rules prescribed thereunder) and the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

d. "Key Managerial Personnel" or KMP means key managerial personnel as defined under the Companies Act, 2013 & in relation to the Company means:-

I. Chief Executive Officer or the Managing Director or the Manager;

II. Company Secretary;

III. Whole Time Director;

IV. Chief Financial Officer; and

V. Such other officer as may be prescribed

e. "Nomination & Remuneration Committee" means "Nomination & Remuneration Committee" constituted by the Board of Directors of the Company from time to time under the provisions of the Companies Act 2013 (including the rules prescribed thereunder) and the Listing Obligations and Disclosure Requirements with the Stock Exchanges.

f. "Other employees" means, all the employees other than Directors, KMPs and the Senior Management Personnel.

g. "Policy" means the Nomination & Remuneration Policy.

"Senior Management Personnel" means, the personnel of the Company who are members of its core management team excluding Board of Directors, comprising of all members of management one level below the Chief Executive Officer/Managing Director/Whole Time Director (including chief executive office, in case he is not part of the board) and shall specifically include company secretary and chief financial officer).

4. Constitution

a. The Board shall determine the membership of the Nomination & Remuneration Committee.

b. The Committee shall comprise of at least three nonexecutive directors, of which not less than one-half shall be independent directors.

c. Chairman of the committee shall be an Independent Director.

d. The Company Secretary shall act as Secretary to the committee.

5. Policy

This policy is divided into three parts:

5.1 Appointment & Removal

a. Criteria for identifying persons who are qualified to be appointed as a Director / KMP / Senior Management Personnel / Other Employees of the Company:

i. The Committee shall consider the ethical standards of integrity and probity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and accordingly recommend to the Board his / her appointment.

ii. The Committee should ensure that the person so appointed as Director/ Independent Director/ KMP/

Senior Management Personnel shall not be disqualified under the Companies Act, 2013, rules made thereunder, Listing Agreement or any other applicable enactment for the time being in force.

iii. The Director/ Independent Director/ KMP/ Senior Management Personnel shall be appointed as per the procedure laid down under the provisions of the Companies Act, 2013, rules made thereunder, Listing Agreement or any other applicable enactment for the time being in force.

iv. The other employees shall be appointed and removed as per the policy and procedure of the Company.

b. Term / Tenure:

The Term / Tenure of the Directors shall be governed as per provisions of the Companies Act, 2013 and rules made thereunder and Listing agreement as amended from time to time.

The Term/Tenure of the KMP's/Senior Management Personnel and other employees shall be as per the companies prevailing policy.

c. Removal:

Due to reasons for any disqualification mentioned in the Companies Act, 2013, rules made thereunder or under any other applicable Act, rules and regulations or any other reasonable ground, the Committee may recommend to the Board for removal of a Director, KMP or a Senior Management Personnel.

The removal of other employees shall be as per the Company's prevailing policy.

d. Retirement:

The director, KMP, senior management personnel & other employees shall retire as per the relevant provisions of the Companies Act, 2013 along with the rules made thereunder and the prevailing policy of the Company, as may be applicable.

The BOD, however, will have the discretion to retain, subject to regulatory approval, if applicable, the Director, KMP, Senior Management Personnel in the same position/remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.

5.2 Remuneration

The level and composition of remuneration to be paid to the Managing Director, Whole-Time Director(s), Non-Executive Director(s), KMP's, Senior Management Personnel and other employees shall be reasonable and sufficient to attract, retain and motivate directors, KMP's, Senior Management and other employees of the quality required to run the company successfully. The relationship of remuneration to performance should be clear and meet appropriate performance benchmarks. The remuneration should also involve a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals.

1. Whole Time Director(s)/ Managing Director

The Whole Time Director(s)/ Managing Director shall be eligible for remuneration as may be approved by the Shareholders of the Company on the recommendation of the Committee and the Board of Directors. The breakup of the pay scale, performance bonus and quantum of perquisites shall be decided and approved by the Board on the recommendation of the Committee and shall be within the overall remuneration approved by the shareholders and Central Government, wherever required.

While recommending the remuneration payable to Whole Time Director(s)/ Managing Director, the Nomination and Remuneration Committee shall, inter alia, have regard to the following matters:

• Financial and operating performance of the Company

• Relationship between remuneration and performance

• Industry/ sector trends for the remuneration paid to executive directorate

Annual Increments to the Whole Time Director(s)/ Managing Director shall be within the slabs approved by the Shareholders. Increments shall be recommended by the Nomination and Remuneration Committee to the Board of Directors at times it desires to do so but preferably on an annual basis.

2. Non-Executive / Independent Directors

i) Remuneration / Commission:

The remuneration / commission shall be fixed as per the slabs and conditions mentioned in the Articles of Association of the Company and the Act.

ii) Sitting Fee:

The Non- Executive / Independent Directors may receive remuneration by way of fees for attending meetings of Board or Committee thereof. Provided that the amount of such fees shall not exceed Rupees One Lakh per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time.

iii) Commission:

Commission may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the profits of the Company computed as per the applicable provisions of the Act.

iv) Stock Options:

An Independent Director shall not be entitled to any stock option of the Company.

3. Senior Management Personnel / KMPs

The Remuneration to be paid to Senior Management Personnel / KMP's shall be based on the experience, qualification, expertise of the related personnel as well as the prevailing market conditions and shall be decided by the Board on the recommendation of Nomination and Remuneration Committee and consonance with the limits, if any prescribed under the Companies Act, 2013 and rules made thereunder or any other applicable enactment for the time being in force.

4. Other Employees

The power to decide structure of remuneration for other employees has been delegated to the CEO & Whole Time Director of the Company who shall decide the same in consultation with the Chief Human Resource Officer of the Company.

5.3 Evaluation

1. Criteria for evaluation of Directors:

As members of the Board, the performance of the individual Directors as well as the performance of the entire Board and its Committees is required to be formally evaluated annually.

In developing the methodology to be used for evaluation, on the basis of best standards and methods meeting international parameters, the Board may consider taking the advice of an Independent Professional Consultant.

2. Criteria for evaluating performance of Key Managerial Personnel and Senior Management Personnel:

The performance evaluation of KMP's and Senior Management Personnel shall be done by their respective reporting heads based on the KRA's given to them at the beginning of the year.

3. Criteria for evaluating performance of Other Employees:

The performance evaluation of other employees shall be done as per Company's Policy.

6. Disclosures

This Policy shall be disclosed on the website of the Company.

7. Amendment(s)

The Board of Directors may review or amend this policy, in whole or in part, from time to time, after taking into account the recommendations from the Nomination & Remuneration Committee.

   

Dr Lal Pathlabs Ltd Company Background

Incorporation Year1995
Registered OfficeE-2 Block Sector 18,Rohini
New Delhi,New Delhi-110085
Telephone91-011-3024 4149,Managing Director
Fax91-011-2788 2134
Company SecretaryRajat Kalra
AuditorDeloitte Haskins & Sells LLP
Face Value10
Market Lot1
ListingBSE,NSE,
RegistrarLink Intime India Pvt Ltd
Noble Heights 1st Fl,Plot NH 2 C-1 Block ,LSC Janakpuri ,New Delhi - 110058

Dr Lal Pathlabs Ltd Company Management

Director NameDirector DesignationYear
Arvind LalChairman cum Managing Director2018
Vandana LalWhole-time Director2018
Om Prakash ManchandaWhole Time Director & CEO2018
Rahul SharmaDirector2018
Arun DuggalIndependent Director2018
Anoop Mahendra SinghIndependent Director2018
Sunil VarmaIndependent Director2018
Harneet Singh ChandhokeIndependent Director2018
Saurabh SrivastavaIndependent Director2018
Rajat KalraCompany Secretary2018
Somya SatsangiIndependent Director2018

Dr Lal Pathlabs Ltd Listing Information

Listing Information
BSE_500
BSE_HC
CNX500
BSESMALLCA
CNXSMALLCA
BSEALLCAP
BSESMALLSE
SML250
MSL400

Dr Lal Pathlabs Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sale of Services NA 0001164.845
Other Operating Revenue NA 0000.054
Sales NA 0000
Scrap Sales NA 0000

Contact us